267 related articles for article (PubMed ID: 16941368)
1. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis comparing prophylactic and preemptive therapies.
Small LN; Lau J; Snydman DR
Clin Infect Dis; 2006 Oct; 43(7):869-80. PubMed ID: 16941368
[TBL] [Abstract][Full Text] [Related]
2. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
Strippoli GF; Hodson EM; Jones C; Craig JC
Transplantation; 2006 Jan; 81(2):139-45. PubMed ID: 16436954
[TBL] [Abstract][Full Text] [Related]
3. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients.
Singh N
Clin Infect Dis; 2001 Mar; 32(5):742-51. PubMed ID: 11229841
[TBL] [Abstract][Full Text] [Related]
4. Prophylaxis and treatment of cytomegalovirus disease in recipients of solid organ transplants: current approach and future challenges.
Puius YA; Snydman DR
Curr Opin Infect Dis; 2007 Aug; 20(4):419-24. PubMed ID: 17609603
[TBL] [Abstract][Full Text] [Related]
5. The case for cytomegalovirus prophylaxis in solid organ transplantation.
Snydman DR
Rev Med Virol; 2006; 16(5):289-95. PubMed ID: 16888821
[TBL] [Abstract][Full Text] [Related]
6. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A
Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909
[TBL] [Abstract][Full Text] [Related]
7. Cytomegalovirus infection in solid organ transplant recipients: new challenges and their implications for preventive strategies.
Singh N
J Clin Virol; 2006 Apr; 35(4):474-7. PubMed ID: 16406798
[TBL] [Abstract][Full Text] [Related]
8. Preemptive versus prophylactic approaches in the management of cytomegalovirus disease in solid organ transplant recipients: what we know and what we do not know.
Meylan PR; Pascual M
Clin Infect Dis; 2006 Oct; 43(7):881-3. PubMed ID: 16941369
[No Abstract] [Full Text] [Related]
9. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation.
Valentine VG; Weill D; Gupta MR; Raper B; Laplace SG; Lombard GA; Bonvillain RW; Taylor DE; Dhillon GS
J Heart Lung Transplant; 2008 Aug; 27(8):875-81. PubMed ID: 18656801
[TBL] [Abstract][Full Text] [Related]
10. A randomized prospective trial of oral versus intravenous ganciclovir for prophylaxis of cytomegalovirus infection and disease in high-risk kidney recipients.
Nafar M; Pezeshki ML; Farrokhi F; Einollahi B; Pour-Reza-Gholi F; Firouzan A; Farhangi S
Transplant Proc; 2005 Sep; 37(7):3053-5. PubMed ID: 16213302
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of different strategies of cytomegalovirus prophylaxis in orthotopic liver transplant recipients.
Das A
Hepatology; 2000 Feb; 31(2):311-7. PubMed ID: 10655251
[TBL] [Abstract][Full Text] [Related]
12. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Ladhani M; Webster AC; Strippoli GF; Craig JC
Cochrane Database Syst Rev; 2013 Feb; (2):CD003774. PubMed ID: 23450543
[TBL] [Abstract][Full Text] [Related]
13. Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipients.
Hodson EM; Barclay PG; Craig JC; Jones C; Kable K; Strippoli GF; Vimalachandra D; Webster AC
Cochrane Database Syst Rev; 2005 Oct; (4):CD003774. PubMed ID: 16235341
[TBL] [Abstract][Full Text] [Related]
14. Prevention of cytomegalovirus disease.
Bailey TC
Semin Respir Infect; 1993 Sep; 8(3):225-32. PubMed ID: 8016483
[TBL] [Abstract][Full Text] [Related]
15. [Cytomegalovirus infection in transplant recipients].
Gondo H
Nihon Rinsho; 1998 Jan; 56(1):173-8. PubMed ID: 9465685
[TBL] [Abstract][Full Text] [Related]
16. Changing impact of cytomegalovirus in liver transplantation -- a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis.
Seehofer D; Rayes N; Neumann UP; Meisel H; Oettle H; Nüssler NC; Jonas S; Langrehr JM; Neuhaus P
Transpl Int; 2005 Aug; 18(8):941-8. PubMed ID: 16008744
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.
Kalil AC; Levitsky J; Lyden E; Stoner J; Freifeld AG
Ann Intern Med; 2005 Dec; 143(12):870-80. PubMed ID: 16365468
[TBL] [Abstract][Full Text] [Related]
18. Improving outcomes for solid-organ transplant recipients at risk from cytomegalovirus infection: late-onset disease and indirect consequences.
Legendre C; Pascual M
Clin Infect Dis; 2008 Mar; 46(5):732-40. PubMed ID: 18220478
[TBL] [Abstract][Full Text] [Related]
19. [Cytomegalovirus infection after solid-organ transplantation, its risk factors, direct and indirect effects and prevention strategies].
Varga M; Remport A; Czebe K; Péter A; Toronyi E; Sárváry E; Fehérvári I; Sulyok B; Járay J
Orv Hetil; 2008 Mar; 149(12):551-8. PubMed ID: 18343771
[TBL] [Abstract][Full Text] [Related]
20. Prevention and management of cytomegalovirus infection in solid-organ transplantation.
Mwintshi K; Brennan DC
Expert Rev Anti Infect Ther; 2007 Apr; 5(2):295-304. PubMed ID: 17402844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]